natgillin/translations-raw huggingface dataset:
[EMA/MB/945561/2011] The Management Board adopted the Agency's preliminary draft work programme 2013. 
(EMA/MB/945561/2011) Upravni odbor je sprejel predhodni osnutek delovnega programa agencije za leto 2013.
There are a number of precursors to adaptive licensing - such as conditional marketing authorisation, new pharmacovigilance legislation, risk-management plans, periodic safety update reports, etc. 
Udeleženci so med razpravo ugotovili, da koncept kot tak na regulativnem področju ni popolnoma nov. Prilagodljivo izdajanje dovoljenj ima več predhodnih korakov, kot so pogojno izdajanje dovoljenj, nova zakonodaja o farmakovigilanci, načrti za obvladovanje tveganj, redno posodobljena poročila o varnosti zdravila itd.
• Consultation no. 15/2011 on the appointment of Esther Werner as CVMP alternate, proposed by Germany, ended, with observations from Members raised in respect of the candidate's expertise, on 3 January 2012. 
• Posvetovanje št. 15/2011 o imenovanju Esther Werner za namestnico v odboru CVMP na predlog Nemčije, končano, člani so 3. januarja 2012 podali pripombe v zvezi s strokovnim znanjem kandidatke.
• Consultation no. 03/2012 on the appointment of Martti Nevalainen as CVMP member, proposed by Finland ended on 2 February 2012 with Members' observations, raised in respect of the candidate's level of conflict of interests and supported by the CVMP Chair, sent to the nominating authority on 13 February 2012. 
• Posvetovanje št. 03/2012 o imenovanju Marttija Nevalainena za člana v odboru CVMP na predlog Finske, končano 2. februarja 2012 s pripombami članov v zvezi s kandidatovim navzkrižjem interesov, te je podprl tudi predsednik odbora CVMP in so bile 13. februarja 2012 poslane organu za imenovanja.
• [EMA/177625/2012 Rev.1] Minutes from the Management Board Telematics Committee meeting held on 14 February 2012. 
• (EMA/177625/2012 Rev. 1) Zapisnik seje odbora za telematiko pri upravnem odboru z dne 14. februarja 2012.
A discussion on the concept of public hearing and transparency 
1. zasedanje: razprava o konceptu javne obravnave in preglednosti
[EMA/154320/2012] The Management Board endorsed the breach of trust procedure on conflicts of interests for scientific-committee members and experts. 
(EMA/154320/2012) Upravni odbor je potrdil postopek pri zlorabi zaupanja v zvezi z navzkrižjem interesov za člane znanstvenih odborov in strokovnjake.
The nominating authority confirmed the withdrawal of the nomination in a letter addressed to the MB Chair, received on 24 February 2012. 
Ta je v dopisu predsedniku upravnega odbora, prejetem 24. februarja 2012, potrdil umik imenovanja.
• Consultation no. 02/2012 on the appointment of Outi Maki-Ikola as CHMP member, proposed by Finland, ended on 26 January 2012. 
• Posvetovanje št. 02/2012 o imenovanju Outi Maki-Ikola za članico v odboru CHMP na predlog Finske, končano 26. januarja 2012.
The mandate of the nominee commenced on 9 December 2011. 
Kandidatka je mandat nastopila 9. decembra 2011.
• Update on the implementation of the pharmacovigilance legislation. 
• najnovejše podatke o izvajanju zakonodaje o farmakovigilanci,
The mandate of the nominee commenced on 4 January 2012. 
Kandidatka je mandat nastopila 4. januarja 2012.
The mandate of the nominee commenced on 27 January 2012. 
Kandidatka je mandat nastopila 27. januarja 2012.
• Publication of agendas and minutes. 
• objavo dnevnih redov in zapisnikov,
• The implementing measures of the pharmacovigilance legislation (planned adoption in Q2 2012). 
• ukrepi za izvajanje zakonodaje o farmakovigilanci (načrtovano sprejetje v drugem četrtletju leta
b.) Preliminary draft budget and establishment plan 2013 
b.) Predhodni predlog proračuna in kadrovski načrt za leto 2013
[EMA/513078/2010] The Management Board endorsed the amendments to the revised conflicts of interests policy for Committee members and experts. 
(EMA/513078/2010) Upravni odbor je potrdil spremembe spremenjene politike o navzkrižju interesov za člane odborov in strokovnjake.
Some outstanding work will be finalised by mid 
Nekaj nedokončanih nalog bo izvedenih do sredine maja 2012.
[EMA/154547/2012] The Board noted the analysis on the implementation of the revised conflicts of interests policy for Committee members and experts. 
(EMA/154547/2012) Upravni odbor se je seznanil z analizo izvajanja spremenjene politike o navzkrižju interesov za člane odborov in strokovnjake.
A gap of one week between PRAC and CHMP/CMD(h) meetings was proposed. 
Predlagan je bil enotedenski premor med sejami odbora PRAC in odbora CHMP/skupine CMD(h).
The meeting also noted the proposal about the timing between PRAC and CHMP/CMD(h) meetings. 
Udeleženci seje so se seznanili še s predlogom časovne uskladitve sej odbora PRAC in odbora CHMP/skupine CMD(h).
• Consultation no. 01/2012 on the appointment of Ingunn Hagen Westgaard as CHMP alternate, proposed by Norway, ended on 26 January 2012. 
• Posvetovanje št. 01/2012 o imenovanju Ingunn Hagen Westgaard za namestnico v odboru CHMP na predlog Norveške, končano 26. januarja 2012.
• Consultation no. 13/2011 on the appointment of Merete Blixenkrone-Moller as CVMP alternate, proposed by Denmark, ended on 8 December 2011. 
• Posvetovanje št. 13/2011 o imenovanju Merete Blixenkrone-Moller za namestnico v odboru CVMP na predlog Danske, končano 8. decembra 2011.
• Consultation no. 14/2011 on the appointment of Ugne Zymantaite as CVMP alternate, proposed by Lithuania, ended on 19 December 2011. 
• Posvetovanje št. 14/2011 o imenovanju Ugne Zymantaite za namestnico v odboru CVMP na predlog Litve, končano 19. decembra 2011.
Representative of veterinarians' organisations Observers 
Predstavnik veterinarskih organizacij
Wednesday meeting, held on 21 March 2012 
Seja, ki je potekala v sredo, 21. marca 2012
EMA/MB/221361/2012 Adopted Management Board 
EMA/518119/2012 sprejet upravni odbor
Thursday meeting, held on 22 March 2012 
Seja, ki je potekala v četrtek, 22. marca 2012
Minutes from the 74th meeting, held on 15 December 
Zapisnik 74. seje, ki je potekala 15. decembra 2011
The mandate of the nominee commenced on 20 December 
Kandidatka je mandat nastopila 20. decembra 2011.
800 mg/150 mg Film-coated tablet Oral use 
800 mg/150 mg filmsko obložena tableta peroralna uporaba plastenka (HDPE)
MA (EU) number (Invented) name 
Številka postopka EMA (Izmišljeno) ime Jakost
Bottle (HDPE) 30 tablets 
30 tablet
This applies to the following conditions: 
To velja za naslednje bolezni:
Duration of Use 
Trajanje uporabe
• if you are using another hormonal contraceptive 
• če uporabljate drug hormonski kontraceptiv
Venous thromboembolism can be fatal in 1-2% of cases. 
Venska trombembolija je lahko v 1 - 2 % primerov smrtna.
The risk is not as high as the risk of developing a blood clot during pregnancy. 
Tveganje ni tako veliko kot tveganje za nastanek krvnega strdka med nosečnostjo.
- obesity (body mass index over 30 kg/m2). 
- debelostjo (indeks telesne mase več kot 30 kg/m²)
In these situations it is advisable to discontinue use (in the case of elective surgery at least four weeks in advance) and not to resume until two weeks after complete remobilisation. 
V teh primerih je priporočljivo jemanje zdravila prekiniti (vsaj štiri tedne pred načrtovanim kirurškim posegom) in ga ponovno začeti jemati šele dva tedna po popolnem okrevanju.
You and your doctor will have to consider all the things that would normally apply to the safe use of oral hormonal contraceptives 
Vi in vaš zdravnik morata upoštevati tudi vse drugo, kar običajno velja za varno uporabo peroralnih hormonskih kontraceptivov.
The symptoms are described in section 2 ‘Blood clots (Thrombosis)'. 
Simptomi so opisani v poglavju 2 "Krvni strdki (tromboza)".
Following a blood clot, recovery is not always complete. 
Okrevanje po krvnem strdku ni vedno popolno.
A full recovery is not always made and in 1-2% of cases, can be fatal. 
Vedno ne pride do popolnega okrevanja, v 1- 2 % primerov pa je nastanek krvnih strdkov lahko smrten.
Possible side effects [This wording should be added under ‘Rare side effects'] Venous blood clot. 
Možni neželeni učinki [To besedilo je treba dodati v “Redki neželeni učinki﻿ krvni strdki v venah
What < invented name > is and what it is used for 
Kaj je zdravilo <ime zdravila> in za kaj ga uporabljamo
Your doctor may then advise you to use a different treatment: 
Vaš zdravnik vam bo morda svetoval uporabo drugih oblik zdravljenja:
• Concomitant use with another hormonal contraceptive (see section 4.1) 
• sočasna uporaba z drugimi hormonskimi kontraceptivi (glejte poglavje 4.1)
For example, a blood clot in an artery in the heart may cause a heart attack, or in the brain may cause a stroke. 
Na primer, krvni strdek v arteriji srca lahko povzroči srčni infarkt, v možganih pa možgansko kap.
with increasing age; if you smoke. 
• če kadite.
Since <invented name> is also a hormonal contraceptive, it should not be used in combination with other hormonal contraceptives (see section 4.3). 
Ker je zdravilo <ime zdravila> tudi hormonski kontraceptiv, se ga ne sme uporabljati sočasno z drugimi hormonskimi kontraceptivi (glejte poglavje 4.3).
Time to relief of symptoms is at least three months. 
Da simptomi izzvenijo mora zdravljenje trajati vsaj tri mesece.
• if you have problems with blood clotting (e.g. protein C deficiency) 
• če imate motnjo strjevanja krvi (npr. pomanjkanje proteina C)
Do not take <invented name> 
Ne jemljite zdravila <ime zdravila>
A blood clot in an artery can cause serious problems. 
Krvni strdek v arteriji lahko povzroči resne težave.
If this applies to you, it is important to tell your doctor that you are using <invented name>, as the treatment may have to be stopped. 
Če karkoli od navedenega velja za vas, je pomembno, da zdravnika opozorite, da uporabljate zdravilo <ime zdravila>, saj bo morda treba zdravljenje prekiniti.
• Epidemiological studies have shown that the incidence of VTE is 1.5 to 2 times higher in users of <invented name> than in users of levonorgestrel-containing combined oral contraceptives (COCs) and may be similar to the risk for desogestrel / gestodene / drospirenone-containing COCs. 
• Epidemiološke študije so pokazale, da je incidenca VTE 1,5-krat do 2-krat večja pri uporabnicah zdravila <ime zdravila>, kot pri uporabnicah kombiniranih peroralnih kontraceptivov, ki vsebujejo levonorgestrel, in je lahko podobna tveganju pri kombiniranih peroralnih kontraceptivih, ki vsebujejo dezogestrel/gestoden/drosperinon.
Due to its contraceptive properties it should only be prescribed for you if your doctor considers that treatment with a hormonal contraceptive is appropriate. 
Zaradi kontraceptivnih lastnosti vam zdravnik lahko to zdravilo predpiše le, če meni, da je za vas primerno, da se zdravite s hormonskim kontraceptivom.
• if you have a condition that may increase the risk of a blood clot in your arteries. 
• če imate kakšno bolezen, ki lahko poveča tveganje za nastanek krvnega strdka v arterijah.
Section 4.8 - Undesirable effects [The wording below should be inserted in this section] 
Poglavje 4.8 - Neželeni učinki [Spodnje besedilo je treba vstaviti v to poglavje]
The risk of blood clots in a vein in users of a combined pill increases further: 
Tveganje za nastanek krvnih strdkov v venah pri uporabnicah kombiniranih kontraceptivov se dodatno poveča:
• Epidemiological studies have also associated the use of hormonal contraceptive with an increased risk for arterial (myocardial infarction, transient ischaemic attack) thromboembolism. 
• V epidemioloških študijah so povezovali uporabo hormonskih kontraceptivov tudi z večjim tveganjem za arterijsko trombembolijo (miokardni infarkt, prehodni ishemični napad).
The need to continue treatment should be evaluated periodically by the treating physician (see section 4.2). 
Lečeči zdravnik mora redno ocenjevati potrebo po nadaljevanju zdravljenja (glejte poglavje 4.2).
The increased risk of thromboembolism in the puerperium must be considered (for information on ‘Pregnancy and lactation' see section 4.6). 
V poporodni dobi je treba upoštevati povečano tveganje za trombembolijo (za informacije o uporabi med nosečnostjo in dojenjem glejte poglavje 4.6).
The physician should then decide on whether the use of <invented name> should be discontinued. 
Zdravnik se bo nato odločil, ali je treba uporabo zdravila <ime zdravila> prekiniti.
<invented name> also works as an oral contraceptive. 
Zdravilo <ime zdravila> deluje tudi kot peroralni kontraceptiv.
Rarely serious permanent disabilities may occur or the blood clot may even be fatal. 
Krvni strdek je lahko redko vzrok za hudo trajno invalidnost ali pa je lahko celo smrten.
If any of the conditions/risk factors mentioned below is present, the benefits of the use of <invented name> should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start using <invented name>. 
Če je prisotno katerokoli od spodaj omenjenih stanj/dejavnikov tveganja, je treba pri vsaki ženski pretehtati koristi in morebitna tveganja uporabe zdravila <ime zdravila> in se o tem z njo pogovoriti, še preden se odloči, da bo zdravilo <ime zdravila> začela uporabljati.
Symptoms of blood clots 
Simptomi krvnih strdkov
A blood clot in a vein (known as a ‘venous thrombosis') can block the vein. 
Krvni strdek v veni (znan tudi kot "venska tromboza") lahko zamaši veno.
Duration of use Your doctor will tell you how long you need to keep taking <invented name>. 
Trajanje uporabe Vaš zdravnik vam bo svetoval, kako dolgo morate jemati zdravilo <ime zdravila>.
<Invented name> is used to treat skin conditions such as acne, very oily skin and excessive hair growth in women of reproductive age. 
Zdravilo <ime zdravila> se uporablja za zdravljenje bolezni kože, kot so akne, čezmerno mastna koža in pretirana poraščenost pri ženskah v rodni dobi.
o diabetes affecting your blood vessels o very high blood pressure o a very high level of fat in your blood (cholesterol or triglycerides) 
o sladkorna bolezen s prizadetostjo krvnih žil o zelo visok krvni tlak o zelo visoke vrednosti maščob v krvi (holesterola ali trigliceridov)
• Hereditary or acquired predisposition for venous or arterial thrombosis, such as activated protein C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant) 
• podedovana ali pridobljena nagnjenost k venski ali arterijski trombozi, npr. odpornost na aktivirani protein C (APC), pomanjkanje antitrombina III, pomanjkanje proteina C, pomanjkanje proteina S, hiperhomocisteinemija in antifosfolipidna protitelesa (antikardiolipinska protitelesa, lupusni antikoagulant)
This can happen in veins of the leg, the lung (a lung embolus), or any other organ. 
To se lahko zgodi v venah nog, pljuč (krvni strdek v pljučih) ali drugih organov.
Blood clots (thrombosis) 
Krvni strdki (tromboza)
In case of suspected or confirmed thrombosis, <invented name> use should be discontinued. 
V primeru suma na trombozo ali potrjene tromboze je treba z jemanjem zdravila <ime zdravila> prekiniti.
Directly after giving birth, women are at an increased risk of blood clots so you should ask your doctor how soon after delivery you can start taking < invented name >. 
Neposredno po porodu je pri ženskah tveganje za nastanek krvnih strdkov povečano, zato se posvetujte z zdravnikom, kdaj po porodu lahko začnete jemati zdravilo <ime zdravila>.
Taking <invented name> may slightly increase your risk of having a blood clot (called a thrombosis). 
Jemanje zdravila <ime zdravila> lahko nekoliko poveča tveganje za nastanek krvnih strdkov (imenovano tromboza).
The need to continue treatment should be evaluated periodically by the treating physician. 
Lečeči zdravnik mora redno ocenjevati potrebo po nadaljevanju zdravljenja.
Your chances of having a blood clot are only increased slightly by taking <invented name> compared with women who do not take <invented name> or any contraceptive pill. 
Možnost, da pri vas nastane krvni strdek, se z jemanjem zdravila <ime zdravila> v primerjavi z ženskami, ki ne jemljejo zdravila <ime zdravila> ali katerega koli drugega kontraceptiva, le malo poveča.
• The user group of <invented name> is likely to include patients that may have an inherently increased cardiovascular risk such as that associated with polycystic ovarian syndrome. 
• V skupini uporabnic zdravila <ime zdravila> bodo verjetno bolnice, ki že imajo povečano tveganje za srčnožilne bolezni, kot na primer tiste povezane s policističnim ovarijskim sindromom.
You should only take <invented name> if your skin condition has not improved after use of other antiacne treatments, including topical treatments and antibiotics. 
Zdravilo <ime zdravila> jemljite za zdravljenje bolezni kože le, če se stanje po uporabi drugih zdravil proti aknam, vključno zdravili za lokalno zdravljenje in antibiotiki, ni izboljšalo.
An increase in frequency or severity of migraine during use of <invented name > (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation of <invented name>. 
Če se pri ženskah, ki uporabljajo zdravilo <ime zdravila>, pogosteje pojavijo migrene ali so te hujše (kar je lahko prodrom cerebrovaskularnega dogodka), je to lahko razlog za takojšnjo prekinitev jemanja zdravila <ime zdravila>.
Women using <invented name> should be specifically pointed out to contact their physician in case of possible symptoms of thrombosis. 
Ženske, ki jemljejo zdravilo <ime zdravila>, je treba posebej opozoriti, da se morajo v primeru možnih simptomov tromboze posvetovati s svojim zdravnikom.
[This section should replace any existing one and should read as follows:] 
[Trenutno odobrene indikacije je treba izbrisati in zamenjati z naslednjim besedilom:]
If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any hormonal contraceptive use. 
Če obstaja sum na dedno nagnjenost, je treba žensko pred odločitvijo za uporabo kateregakoli hormonskega kontraceptiva napotiti po nasvet k specialistu.
In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. 
Ženska naj se v primeru poslabšanja, ponovnega pojava ali prvega pojava katerega koli od teh stanj ali dejavnikov tveganja posvetuje s svojim zdravnikom.
• if you have (or have ever had) a migraine, with visual disturbances 
• če imate (ali ste kdaj imeli) migreno z motnjami vida
• The risk of venous thromboembolic events increases with: - increasing age; - smoking (with heavier smoking and increasing age the risk further increases, especially in women over 35 years of age. 
• Tveganje za nastanek venskih trombemboličnih zapletov se povečuje s: - starostjo - kajenjem (tveganje se še dodatno poveča pri strastnih kadilkah in s starostjo, predvsem pri ženskah, starejših od 35 let.
• Symptoms of venous or arterial thrombosis or of a cerebrovascular accident can include: unusual unilateral leg pain and / or swelling; sudden severe pain in the chest, whether or not it radiates to the left arm; sudden breathlessness; sudden onset of coughing; any unusual, severe, prolonged headache; sudden partial or complete loss of vision; diplopia; slurred speech or aphasia; vertigo; collapse with or without focal seizure; weakness or very marked numbness suddenly affecting one side or one part of the body; motor disturbances; ‘acute' abdomen 
• Simptomi venskih ali arterijskih tromboz ali cerebrovaskularnih dogodkov so lahko: nenavadne bolečine in/ali oteklost ene noge; nenadna huda bolečina v prsnem košu, ki se lahko širi v levo roko; nenadno težko dihanje; nenaden napad kašlja; vsak nenavaden, hud, dolgotrajen glavobol; nenadna delna ali popolna izguba vida; diplopija; nerazločno govorjenje ali afazija; vrtoglavica; kolaps z ali brez žariščnega epileptičnega napada; šibkost ali zelo izrazita omrtvelost, ki nenadoma prizadene eno stran ali en del telesa; motorične motnje; "akutni" abdomen.
When using a hormonal contraceptive like < invented name > you are strongly advised to stop smoking, especially if you are older than 35 years; if you are overweight; if you have high blood pressure; if a close relative has had a heart attack or stroke at a young age; if you have a high level of fat in your blood (cholesterol or triglycerides); if you get migraines; if you have a problem with your heart (valve disorder, disturbance of the rhythm). 
Med uporabo hormonskih kontraceptivov, kot je zdravilo <ime zdravila>, vam strogo odsvetujemo kajenje, še posebej če ste starejši od 35 let; če ste predebeli če imate visok krvni tlak če je kdo od vaših bližnjih sorodnikov v mladosti imel srčni infarkt ali možgansko kap če imate zelo visoke vrednosti maščob v krvi (holesterola ali trigliceridov) če imate napade migrene; če imate težave s srcem (okvaro srčnih zaklopk, motnje srčnega ritma)
The use of a combined pill has been connected with an increased risk of clots in the arteries. 
Uporabo kombiniranih kontraceptivov povezujejo tudi s povečanim tveganjem za nastanek krvnih strdkov v arterijah.
• Venous thrombosis present or in history (deep venous thrombosis, pulmonary embolism) 
• venska tromboza, prisotna ali v anamnezi (globoka venska tromboza, pljučna embolija)
• The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis (see section 4.4) such as: o diabetes mellitus with vascular symptoms o severe hypertension o severe dyslipoproteinaemia 
• prisotnost hudih ali več dejavnikov tveganja za vensko ali arterijsko trombozo (glejte poglavje 4.4), kot so: o sladkorna bolezen z zapleti na ožilju o huda hipertenzija o huda dislipoproteinemija
Section 4.3 Contraindications [The following contraindications related to thromboembolism should be included in this section] 
4.3 Kontraindikacije [Naslednje kontraindikacije je treba vključiti v to poglavje]
The risk of developing a blood clot in a vein is highest during the first year a woman uses the pill. 
Tveganje za nastanek krvnih strdkov v venah je največje prvo leto, ko ženska uporablja kombinirani kontraceptiv.
Using a combined pill increases a woman's risk of developing such clots compared with a woman not taking any combined pill. 
Uporaba kombiniranega kontraceptiva pri ženski poveča tveganje za nastanek krvnih strdkov v primerjavi z ženskami, ki ne jemljejo kombiniranih kontraceptivov.
[The following to be included below the table of adverse reactions] 
[Naslednje besedilo je treba vključiti v preglednico o neželenih učinkih]
• Arterial thromboembolic disorders 
• arterijska trombembolija
The excess risk of VTE is highest during the first year a woman starts <invented name> or when restarting or switching after a pill-free interval of at least a month. 
Povečano tveganje VTE je največje v prvem letu uporabe in sicer pri ženskah, ki so prvič začele uporabljati zdravilo <ime zdravila>, ali pri ženskah, ki so ga ponovno začele uporabljati ali so prešle nanj po vsaj enomesečnem premoru brez jemanja kontracepcijskih tablet.
Other medical conditions, which have been associated with adverse circulatory events, include diabetes mellitus, systemic lupus erythematosus, hemolytic uraemic syndrome, chronic inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis) and sickle cell disease. 
Med drugimi boleznimi, ki jih povezujejo z neugodnimi vplivi na ožilje, so sladkorna bolezen, sistemski eritematozni lupus, hemolitično-uremični sindrom, kronična vnetna črevesna bolezen (Crohnova bolezen ali ulcerozni kolitis) in srpastocelična anemija.
It has a similar composition to that of a combined oral contraceptive (COC). 
Zdravilo ima podobno sestavo kot kombinirani peroralni kontraceptivi.
How to take < invented name > [the wording below should be inserted in the relevant sections] 
Kako jemati zdravilo <ime zdravila> [Spodnje besedilo je treba vstaviti v ustrezna poglavja]
• Arterial thrombosis present or in history (e.g. myocardial infarction) or prodromal conditions (e.g. angina pectoris and transient ischaemic attack). 
• arterijska tromboza, prisotna ali v anamnezi (npr. miokardni infarkt) ali predhodna stanja (npr. angina pektoris in prehodni ishemični napad)